PDT Partners LLC Has $5.84 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• PDT Partners LLC increased its stake in BioCryst Pharmaceuticals by 49.1%, owning 778,729 shares valued at approximately $5.84 million as of its latest SEC filing.
• The company reported an earnings per share (EPS) of $0.15 for the latest quarter, significantly surpassing the consensus estimate of $0.03, and generated $163.35 million in revenue, a 49.5% year-over-year increase.
• Analyst ratings for BioCryst Pharmaceuticals are positive, with a consensus target price of $16.70 and nine investment analysts rating the stock as a "Buy."

PDT Partners LLC lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 49.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 778,729 shares of the biotechnology company's stock after purchasing an additional 256,439 shares during the period. PDT Partners LLC owned about 0.37% of BioCryst Pharmaceuticals worth $5,840,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the first quarter valued at $32,000. GF Fund Management CO. LTD. acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $33,000. GAMMA Investing LLC raised its holdings in BioCryst Pharmaceuticals by 1,161.8% in the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC acquired a new stake in BioCryst Pharmaceuticals in the first quarter valued at $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in BioCryst Pharmaceuticals in the first quarter valued at $79,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded down $0.02 during trading on Thursday, hitting $8.27. 1,576,243 shares of the company were exchanged, compared to its average volume of 3,718,290. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -45.94, a P/E/G ratio of 1.89 and a beta of 1.13. The business's 50-day simple moving average is $8.54 and its 200 day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals's revenue was up 49.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.06) EPS. On average, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BCRX has been the topic of several recent analyst reports. Wedbush upped their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Finally, Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, July 1st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.